Nanobiotix S.A. NBTX
Set alert
31.37 USD -2.43 -7.19%
At close · Oct 30
31.37 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
31.10 Day range 33.44
17.70 52-week range 55.07
- YTD
- +35.68%
- 1 year
- +70.12%
- Open
- 32.50
- Prev close
- 33.80
- Mkt cap
- 1.60B
- Vol
- 235.68K
- Avg vol
- 147.67K
- EPS
- -1.27
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.10
- High
- 33.44
- Forward P/E
- -186.34
- Beta
- 0.59
- Short ratio
- 1.31
- Inst. own
- 11.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 27, 2027
- 50-d avg
- 32.77
- 200-d avg
- 33.80
- 1y target
- 54.04
6M chart
Events in this range
- May 1, 2026Rating: UBS · Neutral → Neutral
- Jun 4, 2026Rating: Leerink Partners · Outperform → Outperform
- Sep 29, 2026Earnings: -0.7981; estimate -0.48457; surprise -64.7%
Signals (43)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 10, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| SMA: Bearish | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| RSI: Overbought | May 13, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.59B
- Enterprise value
- 1.71B
- Trailing P/E
- 0.00
- Forward P/E
- -186.34
- PEG ratio
- 0.00
- Price / sales
- 138.39
- Price / book
- 0.00
- EPS (TTM)
- -1.27
- Beta
- 0.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 11.51M
- Revenue growth
- -79.20%
- Free cash flow
- -32.78M
- Total cash
- 110.89M
- Total debt
- 106.61M
- Return on equity
- 0.00%
- Shares outstanding
- 50.95M
- Short % of float
- 0.52%
- 50-day average
- 32.77
- 200-day average
- 33.80
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 54.04 +72.3% upside
Now 31.37
- Target (low)
- 29.41
- Target (mean)
- 54.04
- Target (high)
- 69.83
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy0
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Apr 27, 2027
Expected Apr 27, 2027. Consensus EPS estimate 0.00.
Financials — quick view
NBTX Revenue — annual 32.59M
NBTX Net income — annual -23.96M
NBTX EPS — annual -0.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 27, 2027 | Dec 30, 2026 | 0.05703 | — | — | — |
| Sep 29, 2026 | Jun 30, 2026 | -0.48457 | -0.7981 | -0.31 | -64.70% |
| Mar 31, 2026 | Dec 31, 2025 | 0.3039 | -0.45809 | -0.76 | -250.74% |
| Sep 30, 2025 | Jun 30, 2025 | -0.24704 | -0.13367 | +0.11 | +45.89% |
| Apr 2, 2025 | Dec 31, 2024 | -0.62 | -1.01 | -0.39 | -63.46% |
| Nov 12, 2024 | Jun 30, 2024 | -0.5117 | -0.49906 | +0.01 | +2.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | main | Outperform | Outperform |
| May 1, 2026 | UBS | main | Neutral | Neutral |
| Apr 2, 2026 | Guggenheim | main | Buy | Buy |
| Feb 6, 2026 | Guggenheim | main | Buy | Buy |
| Apr 4, 2025 | Guggenheim | main | Buy | Buy |
| Aug 28, 2024 | Guggenheim | init | — | Buy |
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- nanobiotix.com
News
- NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
- Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
- Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
- Voting Rights and Shares Capital of the Company
- Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?
- Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?
- NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
- Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY
- NANOBIOTIX Provides First Half 2026 Operational and Financial Update
- Voting Rights and Shares Capital of the Company
Your note
Sign in to keep a note on NBTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 11.06% | 5,623,816 | 175.77M | Sep 29, 2026 |
| Morgan Stanley | 0.10% | 49,789 | 1.56M | Jun 29, 2026 |
| Jane Street Group, LLC | 0.06% | 32,180 | 1.01M | Jun 29, 2026 |
| HRT Financial LP | 0.05% | 27,332 | 854.26K | Jun 29, 2026 |
| Optiver Holding B.v. | 0.03% | 13,631 | 426.04K | Jun 29, 2026 |
| Xtx Topco Ltd | 0.03% | 15,855 | 495.55K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 4,489 | 140.30K | Aug 30, 2026 |
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.00% | 1,048 | 32.76K | Jul 30, 2026 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.00% | 1,649 | 51.54K | Aug 30, 2026 |